Pfizer Explores Use of iPad App for Early Alzheimer’s Detection
Can a game app built for Apple’s (NASDAQ:AAPL) iPad become an invaluable medical tool? Pfizer (NYSE:PFE) recently announced a deal with therapeutic mobile video game maker Akili Interactive Labs to test Project:EVO’s ability to detect the early signs of Alzheimer’s disease. As noted by ReCode, the Project:EVO game app was developed to run on Apple’s iOS platform.
According to Akili Interactive Labs’ website, the company specializes in combining “cutting-edge neuroscience insights, rigorous clinical validation and state-of-the-art game mechanics.” Akili noted that the game app is “designed to quantify and improve the ability of individuals to deal with cognitive interference (distractions and interruptions), which impacts their ability to pay attention, plan and make decisions.”
Under the deal, pharmaceutical giant Pfizer will conduct a clinical trial that will evaluate healthy, elderly subjects with and without the presence of amyloid in their brains. As noted by ReCode, amyloid is the primary component of brain plaques and a known risk factor for the development of Alzheimer’s disease. The goal of the trial is to determine whether or not the Project:EVO game could eventually be used as a clinical tool to determine early signs of Alzheimer’s or other neurodegenerative diseases.